Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Portola Pharmaceuticals, Inc.

Richard G Ball

Anjali Pandey

Nobuyoshi Yasuda

John S Wai

Peter D Williams

Shankar Venkatraman

Wayne J Thompson

Dai-Shi Su

Peter Emmanuel Maligres

Mark W Embrey

Zhiguo Jake Song

Chunhua Yang

Thorsten E Fisher

Tao Pei

Jingjun Yin

David C Dubost

Vincent R Capodanno

Richard C A Isaacs

Michael Shevlin

Neil A Strotman

Dietrich P Steinhuebel

Matthew L Maddess

Eric J Choi

Nancy N Tsou

Robert M Wenslow

James A Mc Cauley

Neil Campbell

Sarah L Trice

Timothy K Maher

Eric L Margelefsky

Itzia Zoraida Arroyo

Michael McNevin

Liam Corcoran

Michael Mcnevin

Matthew Maddess

Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.

Crystalline forms of a factor Xa inhibitor

Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X, X, Y, R, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.

HIV integrase inhibitors

Novel crystalline carbapenem intermediate compounds of formula I: ##STR1## wherein: R.sub.1 represents CH.sub.3 or H and an efficient process for synthesis thereof are described.

Crystalline imidazole complexes as carbapenem intermediates and synthesis

Growing community of inventors

Edison, NJ, United States of America

Richard G Ball